Prima BioMed (ASX:PRR, NASDAQ: PBMD) is a globally active biotechnology company developing immunotherapeutic products for cancer and autoimmune diseases. With operations based in Australia and Europe, Prima BioMed is dedicated to bringing innovative treatment options to market for patients and to maximizing value for shareholders.
Prima's core technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response.
Prima's lead product, IMP321 is in clinical development for the treatment of a range of cancer indications. Three of Prima’s four LAG-3 product candidates have been partnered with pharmaceutical partners including Novartis, GSK and Eddingpharm.
Prima’s newest product candidate, IMP761, is a humanized monoclonal antibody binding to LAG-3+ autoreactive T-cells as an agonist in order to reduce immune reactions in autoimmune diseases.
Prima’s developed autologous cell therapy product known as CVac™ has been licensed to Sydys Inc.
Prima BioMed is listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US (ADR's).